Reversal of dabigatran-induced anticoagulation

Reversal of dabigatran-induced anticoagulation refers to the rapid therapeutic neutralization of the systemic antithrombotic effects produced by dabigatran, an oral direct thrombin inhibitor This clinical state arises in patients receiving dabigatran therapy who develop acute, life-threatening or uncontrolled hemorrhage—such as intracranial or severe gastrointestinal bleeding—or who require emergency surgery or urgent invasive procedures carrying high bleeding risk

Reversal of dabigatran-induced anticoagulation refers to the rapid therapeutic neutralization of the systemic antithrombotic effects produced by dabigatran, an oral direct thrombin inhibitor Pathophysiologically, the drug reversibly binds both free and clot-bound thrombin, thereby impairing fibrin formation, thrombin-mediated platelet activation, and secondary hemostasis, which results in prolonged clotting times and compromised coagulation

This clinical state arises in patients receiving dabigatran therapy who develop acute, life-threatening or uncontrolled hemorrhage—such as intracranial or severe gastrointestinal bleeding—or who require emergency surgery or urgent invasive procedures carrying high bleeding risk Reversal targets the immediate restoration of physiologic hemostasis across the vascular system by counteracting the circulating drug and normalizing thrombin-dependent clot formation

Pathophysiologically, the drug reversibly binds both free and clot-bound thrombin, thereby impairing fibrin formation, thrombin-mediated platelet activation, and secondary hemostasis, which results in prolonged clotting times and compromised coagulation Reversal targets the immediate restoration of physiologic hemostasis across the vascular system by counteracting the circulating drug and normalizing thrombin-dependent clot formation